Wells Fargo & Company Raises Omnicell (NASDAQ:OMCL) Price Target to $41.00

Omnicell (NASDAQ:OMCL) had its price target boosted by Wells Fargo & Company from $30.00 to $41.00 in a research note issued to investors on Monday, Benzinga reports. They currently have an equal weight rating on the stock.

A number of other equities research analysts have also recently commented on the company. JPMorgan Chase & Co. raised their price target on Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a report on Friday, August 23rd. Benchmark reissued a “buy” rating and set a $48.00 price target on shares of Omnicell in a report on Wednesday, October 9th. Bank of America raised their price target on Omnicell from $34.00 to $44.00 and gave the company a “buy” rating in a report on Friday, August 2nd. StockNews.com raised Omnicell from a “hold” rating to a “buy” rating in a report on Thursday, October 10th. Finally, Barclays raised Omnicell from an “underweight” rating to an “equal weight” rating and lifted their target price for the stock from $26.00 to $39.00 in a report on Friday, August 2nd. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Omnicell has an average rating of “Moderate Buy” and a consensus price target of $41.33.

Omnicell Price Performance

NASDAQ OMCL opened at $42.56 on Monday. The company has a market capitalization of $1.95 billion, a PE ratio of -92.52, a price-to-earnings-growth ratio of 47.35 and a beta of 0.83. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.22 and a current ratio of 2.45. The business’s fifty day moving average is $43.19 and its 200 day moving average is $34.10. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $45.84.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, August 1st. The company reported $0.51 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.37. The business had revenue of $276.80 million for the quarter, compared to analysts’ expectations of $254.41 million. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. The business’s quarterly revenue was down 7.4% on a year-over-year basis. During the same period last year, the firm earned $0.29 earnings per share. Sell-side analysts predict that Omnicell will post 0.64 earnings per share for the current year.

Institutional Investors Weigh In On Omnicell

Large investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC increased its stake in Omnicell by 78.4% during the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after acquiring an additional 553 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in Omnicell by 248.8% during the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock worth $38,000 after acquiring an additional 1,000 shares during the last quarter. EntryPoint Capital LLC increased its stake in Omnicell by 121.2% during the first quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock worth $72,000 after acquiring an additional 1,345 shares during the last quarter. CWM LLC increased its stake in Omnicell by 68.2% during the second quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after acquiring an additional 1,236 shares during the last quarter. Finally, Benjamin Edwards Inc. increased its stake in Omnicell by 36.4% during the first quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock worth $95,000 after acquiring an additional 868 shares during the last quarter. 97.70% of the stock is owned by institutional investors.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.